作为细胞膜磷脂酶 A2α 抑制剂的 N,N-二取代 4-氨基磺酰基苯甲酸酯衍生物:合成、水溶性以及在囊泡和全血测定中的活性。

IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Medicinal Chemistry Pub Date : 2024-01-01 DOI:10.2174/0115734064320241240709114041
Daniel Borecki, Imke Meyer Zu Vilsendorf, Jörg Fabian, Matthias Lehr
{"title":"作为细胞膜磷脂酶 A2α 抑制剂的 N,N-二取代 4-氨基磺酰基苯甲酸酯衍生物:合成、水溶性以及在囊泡和全血测定中的活性。","authors":"Daniel Borecki, Imke Meyer Zu Vilsendorf, Jörg Fabian, Matthias Lehr","doi":"10.2174/0115734064320241240709114041","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cytosolic phospholipase A2α (cPLA<sub>2α</sub>) is the key enzyme that initiates the arachidonic acid cascade through which pro-inflammatory lipid mediators can be formed. Therefore, cPLA<sub>2α</sub> is considered an interesting target for the development of anti-inflammatory drugs. Although several effective inhibitors of the enzyme have been developed, none of them has yet reached clinical application.</p><p><strong>Objective: </strong>Recently, we have prepared new 4-sulfamoylbenzoic acid derivatives based on a cPLA<sub>2α</sub> inhibitor found in a ligand-based virtual screening. The most effective of these compounds were now subjected to further variations in which the substitution pattern on the sulfamoyl nitrogen atom was changed..</p><p><strong>Methods: </strong>The new compounds were tested <i>in vitro</i> in a vesicle assay for cPLA<sub>2α</sub> inhibition as well as for their water solubility, metabolic stability, and selectivity towards related enzymes. In addition, they were evaluated <i>ex vivo</i> in a whole blood assay in which metabolites of the arachidonic acid cascade formed after activation of cPLA<sub>2α</sub> were quantified using a combined online dilution/ online solid phase extraction HPLC-MS method.</p><p><strong>Results: </strong>Inhibitors with submicromolar inhibitory <i>in vitro</i> potency were found with favourable water solubility and selectivity. However, their efficacy did not match that of the highly effective, known, structurally related cPLA<sub>2α</sub> inhibitor giripladib, which was also tested as a reference. One advantage of some of the new compounds compared to giripladib was their significantly improved water solubility. When analyzing the substances in the <i>ex vivo</i> whole blood assay, it was found that the obtained inhibition data correlated better with the <i>in vivo</i> results when the phorbol ester 12-Otetradecanoylphorbol- 13-acetate was used for activation of the enzyme in the blood cells instead of the calcium ionophore A23187.</p><p><strong>Conclusion: </strong>New compounds with good activity towards cPLA<sub>2α</sub> and reasonable physicochemical properties were identified. Overall, the results obtained could be helpful in the development of clinically applicable inhibitors of this enzyme.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":"969-985"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<i>N,N</i>-Disubstituted 4-Sulfamoylbenzoic Acid Derivatives as Inhibitors of Cytosolic Phospholipase A<sub>2α</sub>: Synthesis, Aqueous Solubility, and Activity in a Vesicle and a Whole Blood Assay.\",\"authors\":\"Daniel Borecki, Imke Meyer Zu Vilsendorf, Jörg Fabian, Matthias Lehr\",\"doi\":\"10.2174/0115734064320241240709114041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cytosolic phospholipase A2α (cPLA<sub>2α</sub>) is the key enzyme that initiates the arachidonic acid cascade through which pro-inflammatory lipid mediators can be formed. Therefore, cPLA<sub>2α</sub> is considered an interesting target for the development of anti-inflammatory drugs. Although several effective inhibitors of the enzyme have been developed, none of them has yet reached clinical application.</p><p><strong>Objective: </strong>Recently, we have prepared new 4-sulfamoylbenzoic acid derivatives based on a cPLA<sub>2α</sub> inhibitor found in a ligand-based virtual screening. The most effective of these compounds were now subjected to further variations in which the substitution pattern on the sulfamoyl nitrogen atom was changed..</p><p><strong>Methods: </strong>The new compounds were tested <i>in vitro</i> in a vesicle assay for cPLA<sub>2α</sub> inhibition as well as for their water solubility, metabolic stability, and selectivity towards related enzymes. In addition, they were evaluated <i>ex vivo</i> in a whole blood assay in which metabolites of the arachidonic acid cascade formed after activation of cPLA<sub>2α</sub> were quantified using a combined online dilution/ online solid phase extraction HPLC-MS method.</p><p><strong>Results: </strong>Inhibitors with submicromolar inhibitory <i>in vitro</i> potency were found with favourable water solubility and selectivity. However, their efficacy did not match that of the highly effective, known, structurally related cPLA<sub>2α</sub> inhibitor giripladib, which was also tested as a reference. One advantage of some of the new compounds compared to giripladib was their significantly improved water solubility. When analyzing the substances in the <i>ex vivo</i> whole blood assay, it was found that the obtained inhibition data correlated better with the <i>in vivo</i> results when the phorbol ester 12-Otetradecanoylphorbol- 13-acetate was used for activation of the enzyme in the blood cells instead of the calcium ionophore A23187.</p><p><strong>Conclusion: </strong>New compounds with good activity towards cPLA<sub>2α</sub> and reasonable physicochemical properties were identified. Overall, the results obtained could be helpful in the development of clinically applicable inhibitors of this enzyme.</p>\",\"PeriodicalId\":18382,\"journal\":{\"name\":\"Medicinal Chemistry\",\"volume\":\" \",\"pages\":\"969-985\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115734064320241240709114041\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734064320241240709114041","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:细胞膜磷脂酶 A2α(cPLA2α)是启动花生四烯酸级联反应的关键酶,通过该级联反应可形成促炎性脂质介质。因此,cPLA2α 被认为是开发抗炎药物的一个有趣靶点。虽然已经开发出了几种有效的该酶抑制剂,但还没有一种能应用于临床:最近,我们以配体虚拟筛选中发现的一种 cPLA2α 抑制剂为基础,制备了新的 4-氨基磺酰基苯甲酸衍生物。现在,我们对其中最有效的化合物进行了进一步的变异,改变了氨基磺酰基氮原子上的取代模式:方法:在体外囊泡试验中测试了新化合物对 cPLA2α 的抑制作用,以及它们的水溶性、代谢稳定性和对相关酶的选择性。此外,还在全血试验中对它们进行了体内外评估,采用在线稀释/在线固相萃取 HPLC-MS 组合方法对 cPLA2α 激活后形成的花生四烯酸级联代谢产物进行了定量:结果:发现了具有亚摩尔体外抑制效力的抑制剂,它们具有良好的水溶性和选择性。然而,它们的功效与高效、已知、结构相关的 cPLA2a 抑制剂吉利拉地布(giripladib)不相匹配,后者也作为参照物进行了测试。与吉利拉地布相比,一些新化合物的优势在于它们的水溶性显著提高。在体内外全血试验中分析这些物质时发现,如果使用12-Otradecanoylphorbol-13-acetate光甘油酯而不是钙离子诱导剂A23187来激活血细胞中的酶,所获得的抑制数据与体内结果的相关性会更好:结论:发现了对 cPLA2α 具有良好活性和合理理化性质的新化合物。总之,研究结果将有助于开发临床适用的该酶抑制剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
N,N-Disubstituted 4-Sulfamoylbenzoic Acid Derivatives as Inhibitors of Cytosolic Phospholipase A: Synthesis, Aqueous Solubility, and Activity in a Vesicle and a Whole Blood Assay.

Background: Cytosolic phospholipase A2α (cPLA) is the key enzyme that initiates the arachidonic acid cascade through which pro-inflammatory lipid mediators can be formed. Therefore, cPLA is considered an interesting target for the development of anti-inflammatory drugs. Although several effective inhibitors of the enzyme have been developed, none of them has yet reached clinical application.

Objective: Recently, we have prepared new 4-sulfamoylbenzoic acid derivatives based on a cPLA inhibitor found in a ligand-based virtual screening. The most effective of these compounds were now subjected to further variations in which the substitution pattern on the sulfamoyl nitrogen atom was changed..

Methods: The new compounds were tested in vitro in a vesicle assay for cPLA inhibition as well as for their water solubility, metabolic stability, and selectivity towards related enzymes. In addition, they were evaluated ex vivo in a whole blood assay in which metabolites of the arachidonic acid cascade formed after activation of cPLA were quantified using a combined online dilution/ online solid phase extraction HPLC-MS method.

Results: Inhibitors with submicromolar inhibitory in vitro potency were found with favourable water solubility and selectivity. However, their efficacy did not match that of the highly effective, known, structurally related cPLA inhibitor giripladib, which was also tested as a reference. One advantage of some of the new compounds compared to giripladib was their significantly improved water solubility. When analyzing the substances in the ex vivo whole blood assay, it was found that the obtained inhibition data correlated better with the in vivo results when the phorbol ester 12-Otetradecanoylphorbol- 13-acetate was used for activation of the enzyme in the blood cells instead of the calcium ionophore A23187.

Conclusion: New compounds with good activity towards cPLA and reasonable physicochemical properties were identified. Overall, the results obtained could be helpful in the development of clinically applicable inhibitors of this enzyme.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Medicinal Chemistry
Medicinal Chemistry 医学-医药化学
CiteScore
4.30
自引率
4.30%
发文量
109
审稿时长
12 months
期刊介绍: Aims & Scope Medicinal Chemistry a peer-reviewed journal, aims to cover all the latest outstanding developments in medicinal chemistry and rational drug design. The journal publishes original research, mini-review articles and guest edited thematic issues covering recent research and developments in the field. Articles are published rapidly by taking full advantage of Internet technology for both the submission and peer review of manuscripts. Medicinal Chemistry is an essential journal for all involved in drug design and discovery.
期刊最新文献
In Silico Studies of Phytoconstituents to Identify Potential Inhibitors for ERα Protein of Breast Cancer A Preclinical Study on 4-Methyl-N-((4-(trifluoromethoxy)phenyl) carbamoyl)-benzenesulfonamide as a Potent Chemotherapeutic Agent against Liver and Pancreatic Carcinogenesis in Rats: Immunohistochemical and Histopathological Studies Exploring the Diverse Therapeutic Applications of 1, 3-Thiazine: A Comprehensive Review Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights Recent Advances in Anticancer Research of Osmium and Rhodium Complexes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1